CCRA cheat sheet

Source data verification compares the case report form entry against the original medical record; the medical record is the source, the CRF is the transcription, and any discrepancy is documented as a query with resolution date and initials.

Essential documents are filed in the trial master file at the sponsor and the investigator site file at the site; the investigator file must hold the current protocol, signed Form FDA 1572 or equivalent, investigator CV, delegation log, and current IRB/IEC approval.

Investigational product accountability requires a running balance: received minus dispensed minus returned minus destroyed must equal on-hand stock, and any unexplained gap is a protocol deviation requiring documentation.

Informed consent review checks three things in order: the correct current IRB-approved version was used, all required signature and date fields are complete for subject and person obtaining consent, and the consent preceded any study-specific procedure.

Delegation log review confirms each task (consent, assessments, IP dispensing, data entry) is assigned to a named person with documented training and qualifications, and that no task was performed before delegation was recorded.

A monitoring visit report is issued after each visit with a written follow-up letter to the investigator listing findings, action items, responsible persons, and target dates; unresolved items carry forward to the next visit.

Adverse event source review reconciles the AE log, the CRF AE page, the concomitant medication record, and the clinical narrative; an AE treated with a new medication but absent from the AE log is a finding.

Site close-out confirms all queries closed, IP returned or destroyed with documentation, remaining supplies reconciled, and the investigator file complete before the site is released.

Monitoring scope is risk-based: pre-study qualification visit, initiation visit before first subject enrolled, periodic monitoring visits at a frequency justified by enrollment and complexity, and a close-out visit.

Protocol deviation classification: a major deviation affects subject safety, rights, or data integrity (for example missed exclusion criterion or unapproved concomitant medication); a minor deviation is administrative and does not.

Enrollment target tracking compares screened, screen-failed, enrolled, withdrawn, and completed counts; the screen failure rate is screen failures divided by total screened.

Data review timelines are driven by the data management plan: eCRF entry within a defined window after the visit, query response within a defined window, and database lock after all queries resolve and coding completes.

Randomization and blinding checks verify that allocation was obtained in sequence for each eligible subject, that the correct kit number was dispensed, and that no unblinding occurred without documented emergency justification.

Investigational product storage monitoring reviews temperature logs against the labeled range, documents excursions, and confirms sponsor assessment of affected product before further dispensing.

Recruitment and retention monitoring tracks visit windows against the protocol schedule; out-of-window visits are recorded as deviations with the reason and impact on endpoint validity.

Safety reporting timelines: serious adverse events are reported to the sponsor within 24 hours of site awareness, and the sponsor assesses causality and expectedness for expedited regulatory reporting.

Good Clinical Practice rests on three pillars: protection of subject rights, safety, and well-being; credible data; and documented quality systems covering all parties.

IRB/IEC approval must precede any study activity at a site; protocol amendments and consent form changes require approval before implementation, except where needed to eliminate immediate hazard to subjects.

The Declaration of Helsinki sets ethical principles for human research; ICH E6 governs GCP conduct; 21 CFR Parts 50, 56, and 312 govern US informed consent, IRB, and IND requirements respectively.

Informed consent elements include purpose, procedures, risks, benefits, alternatives, confidentiality, compensation and injury provisions, voluntary participation, and contact information for questions and for research-related injury.

Vulnerable populations (children, prisoners, pregnant women, cognitively impaired, economically disadvantaged) require additional safeguards; assent is required from children who can understand, alongside parental permission.

Privacy rules differ by jurisdiction: in the US, HIPAA authorization or a waiver is required to use protected health information for research; in the EU, GDPR requires a lawful basis and explicit consent where applicable.

Regulatory inspection readiness means the investigator file, source documents, IP records, and delegation log are retrievable and current at all times; inspectors may arrive unannounced.

Unanticipated problems involving risk to subjects or others must be reported to the IRB, generally within a defined short window, with a description, the risk assessment, and the corrective action taken.

The follow-up letter is the formal record of a monitoring visit: it restates findings, assigns each action item to a named person with a due date, and is sent within the timeframe set by the sponsor's SOP.

Escalation path: site coordinator, then principal investigator, then sponsor clinical lead, then quality assurance; safety issues escalate immediately and bypass routine sequencing.

Query writing rules: reference the field and visit, state the discrepancy factually, cite the source or protocol section, and avoid leading language that suggests the expected answer.

Site training documentation must capture date, topic, trainer, attendee names, and signatures; training on a protocol amendment is required before any subject undergoes amendment-related procedures.

A pre-study qualification visit assesses investigator qualifications, facility adequacy, subject population access, and staff availability; a negative assessment is documented with reasons.

Communication with the IRB is formal and written for approvals, amendments, and unanticipated problems; informal clarification calls are documented in a file note with date and content.

Escalated unresolved findings are tracked in an issue log with owner, severity, due date, and closure evidence; the log is reviewed at each subsequent visit.

Source data verification compares the case report form entry against the original medical record; the medical record is the source, the CRF is the transcription, and any discrepancy is documented as a query with resolution date and initials.

Essential documents are filed in the trial master file at the sponsor and the investigator site file at the site; the investigator file must hold the current protocol, signed Form FDA 1572 or equivalent, investigator CV, delegation log, and current IRB/IEC approval.

Investigational product accountability requires a running balance: received minus dispensed minus returned minus destroyed must equal on-hand stock, and any unexplained gap is a protocol deviation requiring documentation.

Informed consent review checks three things in order: the correct current IRB-approved version was used, all required signature and date fields are complete for subject and person obtaining consent, and the consent preceded any study-specific procedure.

Delegation log review confirms each task (consent, assessments, IP dispensing, data entry) is assigned to a named person with documented training and qualifications, and that no task was performed before delegation was recorded.

A monitoring visit report is issued after each visit with a written follow-up letter to the investigator listing findings, action items, responsible persons, and target dates; unresolved items carry forward to the next visit.

Adverse event source review reconciles the AE log, the CRF AE page, the concomitant medication record, and the clinical narrative; an AE treated with a new medication but absent from the AE log is a finding.

Site close-out confirms all queries closed, IP returned or destroyed with documentation, remaining supplies reconciled, and the investigator file complete before the site is released.

Monitoring scope is risk-based: pre-study qualification visit, initiation visit before first subject enrolled, periodic monitoring visits at a frequency justified by enrollment and complexity, and a close-out visit.

Protocol deviation classification: a major deviation affects subject safety, rights, or data integrity (for example missed exclusion criterion or unapproved concomitant medication); a minor deviation is administrative and does not.

Enrollment target tracking compares screened, screen-failed, enrolled, withdrawn, and completed counts; the screen failure rate is screen failures divided by total screened.

Data review timelines are driven by the data management plan: eCRF entry within a defined window after the visit, query response within a defined window, and database lock after all queries resolve and coding completes.

Randomization and blinding checks verify that allocation was obtained in sequence for each eligible subject, that the correct kit number was dispensed, and that no unblinding occurred without documented emergency justification.

Investigational product storage monitoring reviews temperature logs against the labeled range, documents excursions, and confirms sponsor assessment of affected product before further dispensing.

Recruitment and retention monitoring tracks visit windows against the protocol schedule; out-of-window visits are recorded as deviations with the reason and impact on endpoint validity.

Safety reporting timelines: serious adverse events are reported to the sponsor within 24 hours of site awareness, and the sponsor assesses causality and expectedness for expedited regulatory reporting.

Good Clinical Practice rests on three pillars: protection of subject rights, safety, and well-being; credible data; and documented quality systems covering all parties.

IRB/IEC approval must precede any study activity at a site; protocol amendments and consent form changes require approval before implementation, except where needed to eliminate immediate hazard to subjects.

The Declaration of Helsinki sets ethical principles for human research; ICH E6 governs GCP conduct; 21 CFR Parts 50, 56, and 312 govern US informed consent, IRB, and IND requirements respectively.

Informed consent elements include purpose, procedures, risks, benefits, alternatives, confidentiality, compensation and injury provisions, voluntary participation, and contact information for questions and for research-related injury.

Vulnerable populations (children, prisoners, pregnant women, cognitively impaired, economically disadvantaged) require additional safeguards; assent is required from children who can understand, alongside parental permission.

Privacy rules differ by jurisdiction: in the US, HIPAA authorization or a waiver is required to use protected health information for research; in the EU, GDPR requires a lawful basis and explicit consent where applicable.

Regulatory inspection readiness means the investigator file, source documents, IP records, and delegation log are retrievable and current at all times; inspectors may arrive unannounced.

Unanticipated problems involving risk to subjects or others must be reported to the IRB, generally within a defined short window, with a description, the risk assessment, and the corrective action taken.

The follow-up letter is the formal record of a monitoring visit: it restates findings, assigns each action item to a named person with a due date, and is sent within the timeframe set by the sponsor's SOP.

Escalation path: site coordinator, then principal investigator, then sponsor clinical lead, then quality assurance; safety issues escalate immediately and bypass routine sequencing.

Query writing rules: reference the field and visit, state the discrepancy factually, cite the source or protocol section, and avoid leading language that suggests the expected answer.

Site training documentation must capture date, topic, trainer, attendee names, and signatures; training on a protocol amendment is required before any subject undergoes amendment-related procedures.

A pre-study qualification visit assesses investigator qualifications, facility adequacy, subject population access, and staff availability; a negative assessment is documented with reasons.

Communication with the IRB is formal and written for approvals, amendments, and unanticipated problems; informal clarification calls are documented in a file note with date and content.

Escalated unresolved findings are tracked in an issue log with owner, severity, due date, and closure evidence; the log is reviewed at each subsequent visit.

Source data verification compares the case report form entry against the original medical record; the medical record is the source, the CRF is the transcription, and any discrepancy is documented as a query with resolution date and initials.

Essential documents are filed in the trial master file at the sponsor and the investigator site file at the site; the investigator file must hold the current protocol, signed Form FDA 1572 or equivalent, investigator CV, delegation log, and current IRB/IEC approval.

Investigational product accountability requires a running balance: received minus dispensed minus returned minus destroyed must equal on-hand stock, and any unexplained gap is a protocol deviation requiring documentation.

Informed consent review checks three things in order: the correct current IRB-approved version was used, all required signature and date fields are complete for subject and person obtaining consent, and the consent preceded any study-specific procedure.

Delegation log review confirms each task (consent, assessments, IP dispensing, data entry) is assigned to a named person with documented training and qualifications, and that no task was performed before delegation was recorded.

A monitoring visit report is issued after each visit with a written follow-up letter to the investigator listing findings, action items, responsible persons, and target dates; unresolved items carry forward to the next visit.

Adverse event source review reconciles the AE log, the CRF AE page, the concomitant medication record, and the clinical narrative; an AE treated with a new medication but absent from the AE log is a finding.

Site close-out confirms all queries closed, IP returned or destroyed with documentation, remaining supplies reconciled, and the investigator file complete before the site is released.

Monitoring scope is risk-based: pre-study qualification visit, initiation visit before first subject enrolled, periodic monitoring visits at a frequency justified by enrollment and complexity, and a close-out visit.

Protocol deviation classification: a major deviation affects subject safety, rights, or data integrity (for example missed exclusion criterion or unapproved concomitant medication); a minor deviation is administrative and does not.

Enrollment target tracking compares screened, screen-failed, enrolled, withdrawn, and completed counts; the screen failure rate is screen failures divided by total screened.

Data review timelines are driven by the data management plan: eCRF entry within a defined window after the visit, query response within a defined window, and database lock after all queries resolve and coding completes.

Randomization and blinding checks verify that allocation was obtained in sequence for each eligible subject, that the correct kit number was dispensed, and that no unblinding occurred without documented emergency justification.

Investigational product storage monitoring reviews temperature logs against the labeled range, documents excursions, and confirms sponsor assessment of affected product before further dispensing.

Recruitment and retention monitoring tracks visit windows against the protocol schedule; out-of-window visits are recorded as deviations with the reason and impact on endpoint validity.

Safety reporting timelines: serious adverse events are reported to the sponsor within 24 hours of site awareness, and the sponsor assesses causality and expectedness for expedited regulatory reporting.

Good Clinical Practice rests on three pillars: protection of subject rights, safety, and well-being; credible data; and documented quality systems covering all parties.

IRB/IEC approval must precede any study activity at a site; protocol amendments and consent form changes require approval before implementation, except where needed to eliminate immediate hazard to subjects.

The Declaration of Helsinki sets ethical principles for human research; ICH E6 governs GCP conduct; 21 CFR Parts 50, 56, and 312 govern US informed consent, IRB, and IND requirements respectively.

Informed consent elements include purpose, procedures, risks, benefits, alternatives, confidentiality, compensation and injury provisions, voluntary participation, and contact information for questions and for research-related injury.

Vulnerable populations (children, prisoners, pregnant women, cognitively impaired, economically disadvantaged) require additional safeguards; assent is required from children who can understand, alongside parental permission.

Privacy rules differ by jurisdiction: in the US, HIPAA authorization or a waiver is required to use protected health information for research; in the EU, GDPR requires a lawful basis and explicit consent where applicable.

Regulatory inspection readiness means the investigator file, source documents, IP records, and delegation log are retrievable and current at all times; inspectors may arrive unannounced.

Unanticipated problems involving risk to subjects or others must be reported to the IRB, generally within a defined short window, with a description, the risk assessment, and the corrective action taken.

The follow-up letter is the formal record of a monitoring visit: it restates findings, assigns each action item to a named person with a due date, and is sent within the timeframe set by the sponsor's SOP.

Escalation path: site coordinator, then principal investigator, then sponsor clinical lead, then quality assurance; safety issues escalate immediately and bypass routine sequencing.

Query writing rules: reference the field and visit, state the discrepancy factually, cite the source or protocol section, and avoid leading language that suggests the expected answer.

Site training documentation must capture date, topic, trainer, attendee names, and signatures; training on a protocol amendment is required before any subject undergoes amendment-related procedures.

A pre-study qualification visit assesses investigator qualifications, facility adequacy, subject population access, and staff availability; a negative assessment is documented with reasons.

Communication with the IRB is formal and written for approvals, amendments, and unanticipated problems; informal clarification calls are documented in a file note with date and content.

Escalated unresolved findings are tracked in an issue log with owner, severity, due date, and closure evidence; the log is reviewed at each subsequent visit.

Source data verification compares the case report form entry against the original medical record; the medical record is the source, the CRF is the transcription, and any discrepancy is documented as a query with resolution date and initials.

Essential documents are filed in the trial master file at the sponsor and the investigator site file at the site; the investigator file must hold the current protocol, signed Form FDA 1572 or equivalent, investigator CV, delegation log, and current IRB/IEC approval.

Investigational product accountability requires a running balance: received minus dispensed minus returned minus destroyed must equal on-hand stock, and any unexplained gap is a protocol deviation requiring documentation.

Informed consent review checks three things in order: the correct current IRB-approved version was used, all required signature and date fields are complete for subject and person obtaining consent, and the consent preceded any study-specific procedure.

Delegation log review confirms each task (consent, assessments, IP dispensing, data entry) is assigned to a named person with documented training and qualifications, and that no task was performed before delegation was recorded.

A monitoring visit report is issued after each visit with a written follow-up letter to the investigator listing findings, action items, responsible persons, and target dates; unresolved items carry forward to the next visit.

Adverse event source review reconciles the AE log, the CRF AE page, the concomitant medication record, and the clinical narrative; an AE treated with a new medication but absent from the AE log is a finding.

Site close-out confirms all queries closed, IP returned or destroyed with documentation, remaining supplies reconciled, and the investigator file complete before the site is released.

Monitoring scope is risk-based: pre-study qualification visit, initiation visit before first subject enrolled, periodic monitoring visits at a frequency justified by enrollment and complexity, and a close-out visit.

Protocol deviation classification: a major deviation affects subject safety, rights, or data integrity (for example missed exclusion criterion or unapproved concomitant medication); a minor deviation is administrative and does not.

Enrollment target tracking compares screened, screen-failed, enrolled, withdrawn, and completed counts; the screen failure rate is screen failures divided by total screened.

Data review timelines are driven by the data management plan: eCRF entry within a defined window after the visit, query response within a defined window, and database lock after all queries resolve and coding completes.

Randomization and blinding checks verify that allocation was obtained in sequence for each eligible subject, that the correct kit number was dispensed, and that no unblinding occurred without documented emergency justification.

Investigational product storage monitoring reviews temperature logs against the labeled range, documents excursions, and confirms sponsor assessment of affected product before further dispensing.

Recruitment and retention monitoring tracks visit windows against the protocol schedule; out-of-window visits are recorded as deviations with the reason and impact on endpoint validity.

Safety reporting timelines: serious adverse events are reported to the sponsor within 24 hours of site awareness, and the sponsor assesses causality and expectedness for expedited regulatory reporting.

Good Clinical Practice rests on three pillars: protection of subject rights, safety, and well-being; credible data; and documented quality systems covering all parties.

IRB/IEC approval must precede any study activity at a site; protocol amendments and consent form changes require approval before implementation, except where needed to eliminate immediate hazard to subjects.

The Declaration of Helsinki sets ethical principles for human research; ICH E6 governs GCP conduct; 21 CFR Parts 50, 56, and 312 govern US informed consent, IRB, and IND requirements respectively.

Informed consent elements include purpose, procedures, risks, benefits, alternatives, confidentiality, compensation and injury provisions, voluntary participation, and contact information for questions and for research-related injury.

Vulnerable populations (children, prisoners, pregnant women, cognitively impaired, economically disadvantaged) require additional safeguards; assent is required from children who can understand, alongside parental permission.

Privacy rules differ by jurisdiction: in the US, HIPAA authorization or a waiver is required to use protected health information for research; in the EU, GDPR requires a lawful basis and explicit consent where applicable.

Regulatory inspection readiness means the investigator file, source documents, IP records, and delegation log are retrievable and current at all times; inspectors may arrive unannounced.

Unanticipated problems involving risk to subjects or others must be reported to the IRB, generally within a defined short window, with a description, the risk assessment, and the corrective action taken.

The follow-up letter is the formal record of a monitoring visit: it restates findings, assigns each action item to a named person with a due date, and is sent within the timeframe set by the sponsor's SOP.

Escalation path: site coordinator, then principal investigator, then sponsor clinical lead, then quality assurance; safety issues escalate immediately and bypass routine sequencing.

Query writing rules: reference the field and visit, state the discrepancy factually, cite the source or protocol section, and avoid leading language that suggests the expected answer.

Site training documentation must capture date, topic, trainer, attendee names, and signatures; training on a protocol amendment is required before any subject undergoes amendment-related procedures.

A pre-study qualification visit assesses investigator qualifications, facility adequacy, subject population access, and staff availability; a negative assessment is documented with reasons.

Communication with the IRB is formal and written for approvals, amendments, and unanticipated problems; informal clarification calls are documented in a file note with date and content.

Escalated unresolved findings are tracked in an issue log with owner, severity, due date, and closure evidence; the log is reviewed at each subsequent visit.

Source data verification compares the case report form entry against the original medical record; the medical record is the source, the CRF is the transcription, and any discrepancy is documented as a query with resolution date and initials.

Essential documents are filed in the trial master file at the sponsor and the investigator site file at the site; the investigator file must hold the current protocol, signed Form FDA 1572 or equivalent, investigator CV, delegation log, and current IRB/IEC approval.

Investigational product accountability requires a running balance: received minus dispensed minus returned minus destroyed must equal on-hand stock, and any unexplained gap is a protocol deviation requiring documentation.

Informed consent review checks three things in order: the correct current IRB-approved version was used, all required signature and date fields are complete for subject and person obtaining consent, and the consent preceded any study-specific procedure.

Delegation log review confirms each task (consent, assessments, IP dispensing, data entry) is assigned to a named person with documented training and qualifications, and that no task was performed before delegation was recorded.

A monitoring visit report is issued after each visit with a written follow-up letter to the investigator listing findings, action items, responsible persons, and target dates; unresolved items carry forward to the next visit.

Adverse event source review reconciles the AE log, the CRF AE page, the concomitant medication record, and the clinical narrative; an AE treated with a new medication but absent from the AE log is a finding.

Site close-out confirms all queries closed, IP returned or destroyed with documentation, remaining supplies reconciled, and the investigator file complete before the site is released.

Monitoring scope is risk-based: pre-study qualification visit, initiation visit before first subject enrolled, periodic monitoring visits at a frequency justified by enrollment and complexity, and a close-out visit.

Protocol deviation classification: a major deviation affects subject safety, rights, or data integrity (for example missed exclusion criterion or unapproved concomitant medication); a minor deviation is administrative and does not.

Enrollment target tracking compares screened, screen-failed, enrolled, withdrawn, and completed counts; the screen failure rate is screen failures divided by total screened.

Data review timelines are driven by the data management plan: eCRF entry within a defined window after the visit, query response within a defined window, and database lock after all queries resolve and coding completes.

Randomization and blinding checks verify that allocation was obtained in sequence for each eligible subject, that the correct kit number was dispensed, and that no unblinding occurred without documented emergency justification.

Investigational product storage monitoring reviews temperature logs against the labeled range, documents excursions, and confirms sponsor assessment of affected product before further dispensing.

Recruitment and retention monitoring tracks visit windows against the protocol schedule; out-of-window visits are recorded as deviations with the reason and impact on endpoint validity.

Safety reporting timelines: serious adverse events are reported to the sponsor within 24 hours of site awareness, and the sponsor assesses causality and expectedness for expedited regulatory reporting.

Good Clinical Practice rests on three pillars: protection of subject rights, safety, and well-being; credible data; and documented quality systems covering all parties.

IRB/IEC approval must precede any study activity at a site; protocol amendments and consent form changes require approval before implementation, except where needed to eliminate immediate hazard to subjects.

The Declaration of Helsinki sets ethical principles for human research; ICH E6 governs GCP conduct; 21 CFR Parts 50, 56, and 312 govern US informed consent, IRB, and IND requirements respectively.

Informed consent elements include purpose, procedures, risks, benefits, alternatives, confidentiality, compensation and injury provisions, voluntary participation, and contact information for questions and for research-related injury.

Vulnerable populations (children, prisoners, pregnant women, cognitively impaired, economically disadvantaged) require additional safeguards; assent is required from children who can understand, alongside parental permission.

Privacy rules differ by jurisdiction: in the US, HIPAA authorization or a waiver is required to use protected health information for research; in the EU, GDPR requires a lawful basis and explicit consent where applicable.

Regulatory inspection readiness means the investigator file, source documents, IP records, and delegation log are retrievable and current at all times; inspectors may arrive unannounced.

Unanticipated problems involving risk to subjects or others must be reported to the IRB, generally within a defined short window, with a description, the risk assessment, and the corrective action taken.

The follow-up letter is the formal record of a monitoring visit: it restates findings, assigns each action item to a named person with a due date, and is sent within the timeframe set by the sponsor's SOP.

Escalation path: site coordinator, then principal investigator, then sponsor clinical lead, then quality assurance; safety issues escalate immediately and bypass routine sequencing.

Query writing rules: reference the field and visit, state the discrepancy factually, cite the source or protocol section, and avoid leading language that suggests the expected answer.

Site training documentation must capture date, topic, trainer, attendee names, and signatures; training on a protocol amendment is required before any subject undergoes amendment-related procedures.

A pre-study qualification visit assesses investigator qualifications, facility adequacy, subject population access, and staff availability; a negative assessment is documented with reasons.

Communication with the IRB is formal and written for approvals, amendments, and unanticipated problems; informal clarification calls are documented in a file note with date and content.

Escalated unresolved findings are tracked in an issue log with owner, severity, due date, and closure evidence; the log is reviewed at each subsequent visit.

Source data verification compares the case report form entry against the original medical record; the medical record is the source, the CRF is the transcription, and any discrepancy is documented as a query with resolution date and initials.

Essential documents are filed in the trial master file at the sponsor and the investigator site file at the site; the investigator file must hold the current protocol, signed Form FDA 1572 or equivalent, investigator CV, delegation log, and current IRB/IEC approval.

Investigational product accountability requires a running balance: received minus dispensed minus returned minus destroyed must equal on-hand stock, and any unexplained gap is a protocol deviation requiring documentation.

Informed consent review checks three things in order: the correct current IRB-approved version was used, all required signature and date fields are complete for subject and person obtaining consent, and the consent preceded any study-specific procedure.

Delegation log review confirms each task (consent, assessments, IP dispensing, data entry) is assigned to a named person with documented training and qualifications, and that no task was performed before delegation was recorded.

A monitoring visit report is issued after each visit with a written follow-up letter to the investigator listing findings, action items, responsible persons, and target dates; unresolved items carry forward to the next visit.

Adverse event source review reconciles the AE log, the CRF AE page, the concomitant medication record, and the clinical narrative; an AE treated with a new medication but absent from the AE log is a finding.

Site close-out confirms all queries closed, IP returned or destroyed with documentation, remaining supplies reconciled, and the investigator file complete before the site is released.

Monitoring scope is risk-based: pre-study qualification visit, initiation visit before first subject enrolled, periodic monitoring visits at a frequency justified by enrollment and complexity, and a close-out visit.

Protocol deviation classification: a major deviation affects subject safety, rights, or data integrity (for example missed exclusion criterion or unapproved concomitant medication); a minor deviation is administrative and does not.

Enrollment target tracking compares screened, screen-failed, enrolled, withdrawn, and completed counts; the screen failure rate is screen failures divided by total screened.

Data review timelines are driven by the data management plan: eCRF entry within a defined window after the visit, query response within a defined window, and database lock after all queries resolve and coding completes.

Randomization and blinding checks verify that allocation was obtained in sequence for each eligible subject, that the correct kit number was dispensed, and that no unblinding occurred without documented emergency justification.

Investigational product storage monitoring reviews temperature logs against the labeled range, documents excursions, and confirms sponsor assessment of affected product before further dispensing.

Recruitment and retention monitoring tracks visit windows against the protocol schedule; out-of-window visits are recorded as deviations with the reason and impact on endpoint validity.

Safety reporting timelines: serious adverse events are reported to the sponsor within 24 hours of site awareness, and the sponsor assesses causality and expectedness for expedited regulatory reporting.

Good Clinical Practice rests on three pillars: protection of subject rights, safety, and well-being; credible data; and documented quality systems covering all parties.

IRB/IEC approval must precede any study activity at a site; protocol amendments and consent form changes require approval before implementation, except where needed to eliminate immediate hazard to subjects.

The Declaration of Helsinki sets ethical principles for human research; ICH E6 governs GCP conduct; 21 CFR Parts 50, 56, and 312 govern US informed consent, IRB, and IND requirements respectively.

Informed consent elements include purpose, procedures, risks, benefits, alternatives, confidentiality, compensation and injury provisions, voluntary participation, and contact information for questions and for research-related injury.

Vulnerable populations (children, prisoners, pregnant women, cognitively impaired, economically disadvantaged) require additional safeguards; assent is required from children who can understand, alongside parental permission.

Privacy rules differ by jurisdiction: in the US, HIPAA authorization or a waiver is required to use protected health information for research; in the EU, GDPR requires a lawful basis and explicit consent where applicable.

Regulatory inspection readiness means the investigator file, source documents, IP records, and delegation log are retrievable and current at all times; inspectors may arrive unannounced.

Unanticipated problems involving risk to subjects or others must be reported to the IRB, generally within a defined short window, with a description, the risk assessment, and the corrective action taken.

The follow-up letter is the formal record of a monitoring visit: it restates findings, assigns each action item to a named person with a due date, and is sent within the timeframe set by the sponsor's SOP.

Escalation path: site coordinator, then principal investigator, then sponsor clinical lead, then quality assurance; safety issues escalate immediately and bypass routine sequencing.

Query writing rules: reference the field and visit, state the discrepancy factually, cite the source or protocol section, and avoid leading language that suggests the expected answer.

Site training documentation must capture date, topic, trainer, attendee names, and signatures; training on a protocol amendment is required before any subject undergoes amendment-related procedures.

A pre-study qualification visit assesses investigator qualifications, facility adequacy, subject population access, and staff availability; a negative assessment is documented with reasons.

Communication with the IRB is formal and written for approvals, amendments, and unanticipated problems; informal clarification calls are documented in a file note with date and content.

Escalated unresolved findings are tracked in an issue log with owner, severity, due date, and closure evidence; the log is reviewed at each subsequent visit.

Source data verification compares the case report form entry against the original medical record; the medical record is the source, the CRF is the transcription, and any discrepancy is documented as a query with resolution date and initials.

Essential documents are filed in the trial master file at the sponsor and the investigator site file at the site; the investigator file must hold the current protocol, signed Form FDA 1572 or equivalent, investigator CV, delegation log, and current IRB/IEC approval.

Investigational product accountability requires a running balance: received minus dispensed minus returned minus destroyed must equal on-hand stock, and any unexplained gap is a protocol deviation requiring documentation.

Informed consent review checks three things in order: the correct current IRB-approved version was used, all required signature and date fields are complete for subject and person obtaining consent, and the consent preceded any study-specific procedure.

Delegation log review confirms each task (consent, assessments, IP dispensing, data entry) is assigned to a named person with documented training and qualifications, and that no task was performed before delegation was recorded.

A monitoring visit report is issued after each visit with a written follow-up letter to the investigator listing findings, action items, responsible persons, and target dates; unresolved items carry forward to the next visit.

Adverse event source review reconciles the AE log, the CRF AE page, the concomitant medication record, and the clinical narrative; an AE treated with a new medication but absent from the AE log is a finding.

Site close-out confirms all queries closed, IP returned or destroyed with documentation, remaining supplies reconciled, and the investigator file complete before the site is released.

Monitoring scope is risk-based: pre-study qualification visit, initiation visit before first subject enrolled, periodic monitoring visits at a frequency justified by enrollment and complexity, and a close-out visit.

Protocol deviation classification: a major deviation affects subject safety, rights, or data integrity (for example missed exclusion criterion or unapproved concomitant medication); a minor deviation is administrative and does not.

Enrollment target tracking compares screened, screen-failed, enrolled, withdrawn, and completed counts; the screen failure rate is screen failures divided by total screened.

Data review timelines are driven by the data management plan: eCRF entry within a defined window after the visit, query response within a defined window, and database lock after all queries resolve and coding completes.

Randomization and blinding checks verify that allocation was obtained in sequence for each eligible subject, that the correct kit number was dispensed, and that no unblinding occurred without documented emergency justification.

Investigational product storage monitoring reviews temperature logs against the labeled range, documents excursions, and confirms sponsor assessment of affected product before further dispensing.

Recruitment and retention monitoring tracks visit windows against the protocol schedule; out-of-window visits are recorded as deviations with the reason and impact on endpoint validity.

Safety reporting timelines: serious adverse events are reported to the sponsor within 24 hours of site awareness, and the sponsor assesses causality and expectedness for expedited regulatory reporting.

Good Clinical Practice rests on three pillars: protection of subject rights, safety, and well-being; credible data; and documented quality systems covering all parties.

IRB/IEC approval must precede any study activity at a site; protocol amendments and consent form changes require approval before implementation, except where needed to eliminate immediate hazard to subjects.

The Declaration of Helsinki sets ethical principles for human research; ICH E6 governs GCP conduct; 21 CFR Parts 50, 56, and 312 govern US informed consent, IRB, and IND requirements respectively.

Informed consent elements include purpose, procedures, risks, benefits, alternatives, confidentiality, compensation and injury provisions, voluntary participation, and contact information for questions and for research-related injury.

Vulnerable populations (children, prisoners, pregnant women, cognitively impaired, economically disadvantaged) require additional safeguards; assent is required from children who can understand, alongside parental permission.

Privacy rules differ by jurisdiction: in the US, HIPAA authorization or a waiver is required to use protected health information for research; in the EU, GDPR requires a lawful basis and explicit consent where applicable.

Regulatory inspection readiness means the investigator file, source documents, IP records, and delegation log are retrievable and current at all times; inspectors may arrive unannounced.

Unanticipated problems involving risk to subjects or others must be reported to the IRB, generally within a defined short window, with a description, the risk assessment, and the corrective action taken.

The follow-up letter is the formal record of a monitoring visit: it restates findings, assigns each action item to a named person with a due date, and is sent within the timeframe set by the sponsor's SOP.

Escalation path: site coordinator, then principal investigator, then sponsor clinical lead, then quality assurance; safety issues escalate immediately and bypass routine sequencing.

Query writing rules: reference the field and visit, state the discrepancy factually, cite the source or protocol section, and avoid leading language that suggests the expected answer.

Site training documentation must capture date, topic, trainer, attendee names, and signatures; training on a protocol amendment is required before any subject undergoes amendment-related procedures.

A pre-study qualification visit assesses investigator qualifications, facility adequacy, subject population access, and staff availability; a negative assessment is documented with reasons.

Communication with the IRB is formal and written for approvals, amendments, and unanticipated problems; informal clarification calls are documented in a file note with date and content.

Escalated unresolved findings are tracked in an issue log with owner, severity, due date, and closure evidence; the log is reviewed at each subsequent visit.